- Investing Ideas
- U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
10
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
10 companies
Illumina
Market Cap: US$20.6b
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
ILMN
US$139.37
7D
8.4%
1Y
78.3%
Exelixis
Market Cap: US$11.1b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$44.17
7D
-1.1%
1Y
10.9%
ACADIA Pharmaceuticals
Market Cap: US$3.8b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$22.19
7D
-0.5%
1Y
46.6%
ADMA Biologics
Market Cap: US$2.4b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$10.31
7D
-5.7%
1Y
-56.5%
Aurinia Pharmaceuticals
Market Cap: US$2.0b
A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
AUPH
US$15.77
7D
-3.7%
1Y
90.9%
Theravance Biopharma
Market Cap: US$864.6m
A biopharmaceutical company, develops and commercializes medicines in the United States.
TBPH
US$16.91
7D
0.6%
1Y
64.3%
CorMedix
Market Cap: US$611.0m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$7.90
7D
1.0%
1Y
-12.5%
Abeona Therapeutics
Market Cap: US$338.2m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$5.95
7D
11.0%
1Y
3.4%
Compugen
Market Cap: US$256.2m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.64
7D
-9.6%
1Y
92.7%
Oramed Pharmaceuticals
Market Cap: US$161.0m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$3.93
7D
-4.4%
1Y
70.1%